ERBB3 and lung carcinoma: Intriguingly, in EGFR-mutant HCC827 lung cancer cells subjected to prolonged gefitinib treatment in tissue culture, an acquired resistance mechanism involved MET gene amplification, Met-dependent HER3–tyrosine phosphorylation, and HER3-dependent activation of PI3K downstream of Met [26].